- Home
- SRV vs LXEO Comparison
SRV vs LXEO Comparison
Compare SRV & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- LXEO
- Stock Information
- Founded
- SRV 2007
- LXEO 2017
- Country
- SRV United States
- LXEO United States
- Employees
- SRV N/A
- LXEO N/A
- Industry
- SRV Finance Companies
- LXEO
- Sector
- SRV Finance
- LXEO
- Exchange
- SRV Nasdaq
- LXEO Nasdaq
- Market Cap
- SRV 136.9M
- LXEO 140.6M
- IPO Year
- SRV N/A
- LXEO 2023
- Fundamental
- Price
- SRV $45.87
- LXEO $3.89
- Analyst Decision
- SRV
- LXEO Strong Buy
- Analyst Count
- SRV 0
- LXEO 5
- Target Price
- SRV N/A
- LXEO $23.80
- AVG Volume (30 Days)
- SRV 33.9K
- LXEO 246.3K
- Earning Date
- SRV 01-01-0001
- LXEO 03-04-2025
- Dividend Yield
- SRV 13.38%
- LXEO N/A
- EPS Growth
- SRV N/A
- LXEO N/A
- EPS
- SRV N/A
- LXEO N/A
- Revenue
- SRV N/A
- LXEO N/A
- Revenue This Year
- SRV N/A
- LXEO N/A
- Revenue Next Year
- SRV N/A
- LXEO N/A
- P/E Ratio
- SRV N/A
- LXEO N/A
- Revenue Growth
- SRV N/A
- LXEO N/A
- 52 Week Low
- SRV $30.73
- LXEO $3.84
- 52 Week High
- SRV $44.30
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- SRV 47.40
- LXEO 33.05
- Support Level
- SRV $45.81
- LXEO $3.84
- Resistance Level
- SRV $47.96
- LXEO $4.72
- Average True Range (ATR)
- SRV 0.86
- LXEO 0.53
- MACD
- SRV -0.09
- LXEO -0.05
- Stochastic Oscillator
- SRV 45.40
- LXEO 2.27
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.